6. November 2020 blir en viktig milepæl for BerGenBio.

Agenda
(times in CET)

13:00
Introduction - Richard Godfrey, Chief Executive Officer, BerGenBio


Presentations from independent AXL experts, followed by Q&A sessions led by James Lorens, Chief Scientific Officer and Hani Gabra, Chief Medical Officer at BerGenBio

13:10
AXL in AML/MDS – Professor Sonja Loges, Director, Department of Personalised Oncology, University Hospital Mannheim and Division of Personalised Medical Oncology, German Cancer Research Center - DKFZ (Heidelberg, Germany)

13:40
AXL in lung cancer – Dr Matthew Krebs, Clinical Senior Lecturer in Experimental Cancer Medicine and Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust (Manchester, UK)


14:10
AXL and viruses/COVID-19 – Professor Wendy Maury, Professor of Microbiology and Immunology, University of Iowa (Iowa City, USA)

14:40
AXL in fibrosis/IPF – Professor Cory Hogaboam, Professor of Medicine, Cedars-Sinai Medical Center (Los Angeles, USA)

15:10
Bemcentinib clinical development plan - Hani Gabra, Chief Medical Officer, BerGenBio

15:25
Concluding remarks - Richard Godfrey, Chief Executive Officer, BerGenBio


For further information, please contact Consilium Strategic Communications at bergenbio@consilium-comms.com or ir@bergenbio.com

Spesielt ser jeg frem til presentasjonen Kl 14:10

AXL and viruses/COVID-19 – Professor Wendy Maury, Professor of Microbiology and Immunology, University of Iowa (Iowa City, USA)

Dr. Wendy Maury arbeider med COVID-19 og Bemcentinib.
https://uihc.org/news/university-iowa-virology-research-helps-facilitate-new-clinical-trial-covid-19

Phase III og FDA approval på Bemcentinib mot COVID-19 m.v. håper og tror jeg er nært forestående.